                         SEQUENCE LISTING

<110>  Zaklady Farmaceutyczne Polpharma SA
 
<120>  Recombinant Production Of Monoclonal Antibodies

<130>  

<160>  4     

<170>  PatentIn version 3.5

<210>  1
<211>  699
<212>  DNA
<213>  Artificial

<220>
<223>  Light Chain Natalizumab


<220>
<221>  sig_peptide
<222>  (1)..(54)
<223>  SP(3)

<400>  1
atgaagtggg tgaccttcat ctccctgctg tttctgttct cctccgccta ctccgacatc       60

cagatgaccc agtccccctc cagcctgtcc gcctccgtgg gcgacagagt gaccatcaca      120

tgcaagacct cccaggacat caacaagtac atggcctggt atcagcagac ccccggcaag      180

gcccctcggc tgctgatcca ctacacctcc gccctgcagc ccggcatccc ttccagattc      240

tccggctctg gctctggccg ggactacacc ttcaccatct ccagcctgca gcctgaggac      300

attgccacct actactgcct gcagtacgac aacctgtgga ccttcggcca gggcaccaag      360

gtggaaatca agcggaccgt ggccgctccc tccgtgttca tcttcccacc ctccgacgag      420

cagctgaagt ccggcaccgc cagcgtggtg tgcctgctga acaacttcta cccccgcgag      480

gccaaggtgc agtggaaggt ggacaacgcc ctgcagagcg gcaactccca ggaatccgtg      540

accgagcagg actccaagga cagcacctac tccctgtcct ccaccctgac cctgtccaag      600

gccgactacg agaagcacaa ggtgtacgcc tgcgaagtga cccaccaggg cctgtccagc      660

cccgtgacca agtccttcaa ccggggcgag tgctgatag                             699


<210>  2
<211>  231
<212>  PRT
<213>  Artificial

<220>
<223>  Light Chain Natalizumab


<220>
<221>  SIGNAL
<222>  (1)..(18)
<223>  SP(3)

<220>
<221>  mat_peptide
<222>  (19)..(231)

<400>  2

Met Lys Trp Val Thr Phe Ile Ser Leu Leu Phe Leu Phe Ser Ser Ala 
            -15                 -10                 -5          


Tyr Ser Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser 
    -1  1               5                   10                  


Val Gly Asp Arg Val Thr Ile Thr Cys Lys Thr Ser Gln Asp Ile Asn 
15                  20                  25                  30  


Lys Tyr Met Ala Trp Tyr Gln Gln Thr Pro Gly Lys Ala Pro Arg Leu 
                35                  40                  45      


Leu Ile His Tyr Thr Ser Ala Leu Gln Pro Gly Ile Pro Ser Arg Phe 
            50                  55                  60          


Ser Gly Ser Gly Ser Gly Arg Asp Tyr Thr Phe Thr Ile Ser Ser Leu 
        65                  70                  75              


Gln Pro Glu Asp Ile Ala Thr Tyr Tyr Cys Leu Gln Tyr Asp Asn Leu 
    80                  85                  90                  


Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala 
95                  100                 105                 110 


Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser 
                115                 120                 125     


Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu 
            130                 135                 140         


Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser 
        145                 150                 155             


Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu 
    160                 165                 170                 


Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val 
175                 180                 185                 190 


Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys 
                195                 200                 205     


Ser Phe Asn Arg Gly Glu Cys 
            210             


<210>  3
<211>  1410
<212>  DNA
<213>  Artificial

<220>
<223>  Heavy Chain Natalizumab


<220>
<221>  sig_peptide
<222>  (1)..(54)
<223>  SP(3)

<400>  3
atgaagtggg tgaccttcat ctccctgctg tttctgttct ccagcgccta ctcccaggtg       60

cagctggtgc agtctggcgc cgaagtgaag aaacctggcg cctccgtgaa ggtgtcctgc      120

aaggcctccg gcttcaacat caaggacacc tacatccact gggtgcgaca ggcccctggc      180

cagcggctgg aatggatggg cagaatcgac cccgccaacg gctacactaa gtacgacccc      240

aagttccagg gcagagtgac catcaccgcc gacacctccg cctccaccgc ctacatggaa      300

ctgtcctccc tgcggagcga ggacaccgcc gtgtactact gcgccagaga gggctactac      360

ggcaactacg gcgtgtacgc catggactac tggggccagg gcaccctggt gacagtgtcc      420

tccgccagca ccaagggccc ctccgtgttc cctctggccc cttgctcccg gtccacctcc      480

gagtctaccg ccgctctggg ctgcctggtg aaagactact tccccgagcc cgtgaccgtg      540

tcctggaact ctggcgccct gacctccggc gtgcacacct tccctgccgt gctgcagtcc      600

tccggcctgt actccctgtc ctccgtggtg accgtgccat ccagctccct gggcaccaag      660

acctacacct gtaacgtgga ccacaagccc tccaacacca aggtggacaa gcgggtggaa      720

tctaagtacg gccctccctg ccccagctgc cctgcccctg aattcctggg cggaccttcc      780

gtgttcctgt tccccccaaa gcccaaggac accctgatga tctcccggac ccccgaagtg      840

acctgcgtgg tggtggacgt gtcccaggaa gatcccgagg tgcagttcaa ttggtacgtg      900

gacggcgtgg aagtgcacaa cgccaagacc aagcccagag aggaacagtt caactccacc      960

taccgggtgg tgtctgtgct gaccgtgctg caccaggact ggctgaacgg caaagagtac     1020

aagtgcaagg tgtccaacaa gggcctgccc agctccatcg aaaagaccat ctccaaggcc     1080

aagggccagc cccgcgagcc ccaggtgtac accctgcccc ctagccagga agagatgacc     1140

aagaaccagg tgtccctgac ctgtctggtg aaaggcttct acccctccga cattgccgtg     1200

gaatgggagt ccaacggcca gcccgagaac aactacaaga ccaccccccc tgtgctggac     1260

tccgacggct ccttcttcct gtactctcgg ctgaccgtgg acaagtcccg gtggcaggaa     1320

ggcaacgtgt tctcctgctc cgtgatgcac gaggccctgc acaaccacta cacccagaag     1380

tccctgtccc tgagcctggg caagtgatag                                      1410


<210>  4
<211>  468
<212>  PRT
<213>  Artificial

<220>
<223>  Heavy Chain Natalizumab


<220>
<221>  SIGNAL
<222>  (1)..(18)
<223>  SP(3)

<220>
<221>  mat_peptide
<222>  (19)..(468)

<400>  4

Met Lys Trp Val Thr Phe Ile Ser Leu Leu Phe Leu Phe Ser Ser Ala 
            -15                 -10                 -5          


Tyr Ser Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro 
    -1  1               5                   10                  


Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Phe Asn Ile Lys 
15                  20                  25                  30  


Asp Thr Tyr Ile His Trp Val Arg Gln Ala Pro Gly Gln Arg Leu Glu 
                35                  40                  45      


Trp Met Gly Arg Ile Asp Pro Ala Asn Gly Tyr Thr Lys Tyr Asp Pro 
            50                  55                  60          


Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Thr Ser Ala Ser Thr 
        65                  70                  75              


Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr 
    80                  85                  90                  


Tyr Cys Ala Arg Glu Gly Tyr Tyr Gly Asn Tyr Gly Val Tyr Ala Met 
95                  100                 105                 110 


Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr 
                115                 120                 125     


Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Cys Ser Arg Ser Thr Ser 
            130                 135                 140         


Glu Ser Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu 
        145                 150                 155             


Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His 
    160                 165                 170                 


Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser 
175                 180                 185                 190 


Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Lys Thr Tyr Thr Cys 
                195                 200                 205     


Asn Val Asp His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu 
            210                 215                 220         


Ser Lys Tyr Gly Pro Pro Cys Pro Ser Cys Pro Ala Pro Glu Phe Leu 
        225                 230                 235             


Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu 
    240                 245                 250                 


Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser 
255                 260                 265                 270 


Gln Glu Asp Pro Glu Val Gln Phe Asn Trp Tyr Val Asp Gly Val Glu 
                275                 280                 285     


Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Phe Asn Ser Thr 
            290                 295                 300         


Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn 
        305                 310                 315             


Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Gly Leu Pro Ser Ser 
    320                 325                 330                 


Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln 
335                 340                 345                 350 


Val Tyr Thr Leu Pro Pro Ser Gln Glu Glu Met Thr Lys Asn Gln Val 
                355                 360                 365     


Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val 
            370                 375                 380         


Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro 
        385                 390                 395             


Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Arg Leu Thr 
    400                 405                 410                 


Val Asp Lys Ser Arg Trp Gln Glu Gly Asn Val Phe Ser Cys Ser Val 
415                 420                 425                 430 


Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu 
                435                 440                 445     


Ser Leu Gly Lys 
            450 


